Novo Nordisk stock faces FDA warning over rare eye risk

On Monday, November 9, 2026, the U.S. Food and Drug Administration required manufacturers of GLP-1 medicines to add warnings about a potential increased risk of nonarteritic anterior ischemic optic neuropathy, or NAION. CNBC reported that the rare condition can cause sudden vision loss, including permanent impairment.

Regulatory focus shifts to labeling

The FDA action covers marketed GLP-1 products, including Novo Nordisk medicines Wegovy and Ozempic. The agency cited clinical-trial reviews, real-world patient information and published studies, while noting that the evidence does not establish a causal relationship.

Novo Nordisk said it continues to believe the available data do not establish cause and effect and remains confident in the benefit-risk profile of its GLP-1 medicines. For investors, the labeling change adds a safety-monitoring issue to the commercial outlook for the company's obesity and diabetes portfolio.

Weekly share performance remains positive

Novo Nordisk stock traded at 37.78 euros on Lang & Schwarz at 12:00 CET on Saturday, November 14, 2026, 1.72 percent above the Xetra close of Friday, November 13. The Xetra close advanced 2.71 percent over the week from Friday, November 6, to Friday, November 13, based on the historical closing prices published by Yahoo Finance.

The wider market environment can be followed in current market reports.

See more news and analyses on Novo Nordisk stock.